Welcome to LookChem.com Sign In|Join Free

CAS

  • or

81466-36-6

Post Buying Request

81466-36-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

81466-36-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 81466-36-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,1,4,6 and 6 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 81466-36:
(7*8)+(6*1)+(5*4)+(4*6)+(3*6)+(2*3)+(1*6)=136
136 % 10 = 6
So 81466-36-6 is a valid CAS Registry Number.

81466-36-6Relevant articles and documents

Synthesis and biological evaluation of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists

Wang, Xuekun,Zhao, Tianxiao,Yang, Baowei,Li, Zheng,Cui, Jian,Dai, Yuxuan,Qiu, Qianqian,Qiang, Hao,Huang, Wenlong,Qian, Hai

, p. 132 - 140 (2015/02/18)

Free fatty acid receptor 1 (FFA1) is a new potential drug target for the treatment of type 2 diabetes because of its role in amplifying glucose-stimulated insulin secretion in pancreatic β-cell. In the present studies, we identified phenoxyacetic acid derivative (18b) as a potent FFA1 agonist (EC50 = 62.3 nM) based on the structure of phenylpropanoic acid derivative 4p. Moreover, compound 18b could significantly improve oral glucose tolerance in ICR mice and dose-dependently reduced glucose levels in type 2 diabetic C57BL/6 mice without observation of hypoglycemic side effect. Additionally, compound 18b exhibited acceptable PK profiles. In summary, compound 18b with ideal PK profiles exhibited good activity in vitro and in vivo, and might be a promising drug candidate for the treatment of diabetes mellitus.

COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS

-

Page/Page column 54, (2010/11/27)

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families.

Design and synthesis of potent and subtype-selective PPARα agonists

Desai, Ranjit C.,Metzger, Edward,Santini, Conrad,Meinke, Peter T.,Heck, James V.,Berger, Joel P.,MacNaul, Karen L.,Cai, Tian-Quan,Wright, Samuel D.,Agrawal, Arun,Moller, David E.,Sahoo, Soumya P.

, p. 1673 - 1678 (2007/10/03)

Beginning with a moderately potent PPARγ agonist 9, a series of potent and highly subtype-selective PPARα agonists was identified through a systematic SAR study. Based on the results of the efficacy studies in the hamster and dog models of dyslipidemia and the desired pharmacokinetic data, the optimized compound 39 was selected for further profiling.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 81466-36-6